Roche and Hansoh Enter Cancer-Therapy Licensing Deal Worth Up to $15 Billion
Roche Holding entered a collaboration and licensing agreement with Hansoh Pharmaceutical Group centered on cancer therapies. The deal could net Hansoh more than $15 billion.
By Adria CalatayudRoche Holding entered into a collaboration and licensing agreement with Hansoh Pharmaceutical Group, continuing a dealmaking spree in China with a partnership that could net the Chinese drugmaker more than $15 billion.The latest deal with Hansoh, centered on cancer therapies, foll…